{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', \"exclusion criteria is inadvertently randomized and dosed, the Medical Monitor at Sponsor's\", \"Designated CRO and the Sponsor's Medical Director must be contacted immediately.\", '4.4.1.', 'Early Discontinuation from Trial', 'Early discontinuation from the trial is defined as the permanent cessation of further', 'participation in the trial prior to its planned completion. Patients must be discontinued early', 'from the trial and complete the EoS/ED visit if:', 'they withdraw their consent', 'the randomization code is broken prematurely by the Investigator or his/her staff', \"the Investigator, after discussion with the Sponsor's Medical Director, deems it is in the\", \"patient's best interest.\", 'All patients are free to withdraw consent from participation in the trial at any time, for any', 'reason, specified or unspecified, and without prejudice to further treatment. Prior to actual', 'withdrawal of consent, an effort should be made to perform a final set of assessments as per', 'EoS/ED visit in the general SoA (Table 1). Investigators will make and document all efforts', 'made to contact those patients who do not return for scheduled visits.', 'The reason for early discontinuation from the trial will be clearly documented by the', 'Investigator.', '4.4.2.', 'Early Discontinuation from Randomized Treatment', 'Early discontinuation from randomized treatment means that the patient stops receiving the', 'ongoing treatment and will never start a new Treatment Cycle for the entire duration of the', 'trial; however informed consent is not withdrawn. These patients will continue to be', 'followed up in the trial according to the SoA for Patients who Discontinued Early from', 'Randomized Treatment (Table 2).', 'Patients must be discontinued early from randomized treatment if:', 'Patient is pregnant', 'Patients receives rescue therapy', 'Patient develops an SAE that is likely to result in a life-threatening situation or pose a', 'serious safety risk.', 'Prohibited medication is taken (see Section 6.8.1)', 'Patients might discontinue early from randomized treatment:', 'argenx BVBA', 'Confidential', 'Page 59 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'In case the patient has clinical evidence of bacterial, viral or fungal disease or any other', 'significant disease which could confound the results of the trial or put the patient at', 'undue risk. In this situation, decision on whether or not to discontinue patients early from', 'randomized treatment will depend on the evaluation on a case by case basis. Patients', 'who, after evaluation of the above situations, are not discontinued from randomized', 'treatment, may have a temporary interruption from randomized treatment (see', 'Section 4.4.3).', 'Patients who discontinue early from randomized treatment within a Treatment Cycle will', 'have to complete the EoT assessments and complete the remaining visits in the current', 'Treatment Cycle, according to the general SoA (Table 1). These patients will not receive any', 'further IMP administration during the trial and will continue to be followed for safety and', 'disease severity (limited to MG-ADL and QMG) as per the SoA for Patients who', 'Discontinued Early from Randomized Treatment (Table 2).', 'Patients who discontinue early from randomized treatment in the ITC period will have to', 'complete the EoT assessments and then continue into the Safety and Disease Severity', 'Follow-up period as per Table 2.', '4.4.3.', 'Temporary Interruption from Randomized Treatment', 'A patient that does not need to be discontinued early from randomized treatment might still', 'have a temporary interruption from randomized treatment. A temporary interruption from', 'randomized treatment is defined as a discontinuation of the current Treatment Cycle but the', 'patient might still be eligible for further additional treatments with IMP within this trial.', 'Patients for whom treatment is interrupted will have to complete the current Treatment Cycle', 'and will continue the trial as per general SoA (Table 1).', '4.4.4.', 'Missed Doses', 'Patients who miss one, two or three infusions per Treatment Cycle will stay in the trial and', 'will follow the assessments as per general SoA (Table 1). These patients may be eligible for', 'further Treatment Cycles during the trial.', '4.5.', 'Roll-Over to Follow-on Trial', 'At EoS, patients will be offered the option to roll over into a long-term, single-arm, open-', 'label follow-on trial (ARGX-113-1705) where they will be treated with ARGX-113', '(10 mg/kg of body weight) on an \"as needed basis\".', 'Patients who need re-treatment but cannot complete a Treatment Cycle within the time frame', 'of the ARGX-113-1704 trial (i.e., require re-treatment after Day 127), may roll over', 'immediately to the follow-on trial to receive treatment with ARGX-113.', 'argenx BVBA', 'Confidential', 'Page 60 of 110']\n\n###\n\n", "completion": "END"}